Syndax Pharmaceuticals (NASDAQ: SNDX) reported Q2 EPS of ($0.83), $0.18 better than the analyst estimate of ($1.01). Revenue for the quarter came in at $37.96 million versus the consensus estimate of $27.13 million.

For earnings history and earnings-related data on Syndax Pharmaceuticals (SNDX) click here.